Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Equity Dilution
AIAI Summary
Celldex is now a high-risk clinical execution bet: despite ample liquidity, the barzolvolimab Phase 2 failure raises the proof threshold for its core asset, so investors should wait for convincing follow-on efficacy data and monitor burn-driven dilution rather than rely on cash as downside protection.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Equity Dilution
CLDX is well-capitalized with substantial liquidity and minimal debt, but severe losses, cash burn, negligible revenue, and equity dilution make it a high-risk, financing-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Downward bias
- •Fragile rebound
- •Weak momentum
CLDX remains technically weak over the last month, with downside risk below $36.90 and a more constructive outlook only if it reclaims $39.70–$40.40.
Rebound to $39.18 failed to hold after the $36.90 low
Sentiment & News
Key News Insights:
- •Shareholder Investigation
- •Investor Outreach
- •Institutional Buying
Celldex faces shareholder scrutiny while boosting investor engagement and attracting new institutional ownership.
Governance concerns may temper sentiment, though institutional buying and conference visibility provide modest support
Similar Companies in Healthcare
Other companies in the same sector with AI ratings